Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Dermatological Drugs - Iceland

Iceland
  • The Dermatological Drugs market in Iceland is expected to see a significant increase in revenue, reaching US$4.47m in 2024.
  • This projection anticipates a steady annual growth rate (CAGR 2024-2029) of 6.78%, leading to a market volume of US$6.21m by 2029.
  • When compared to other countries worldwide, United States is projected to generate the highest revenue in this market, amounting to US$11.67bn in 2024.
  • In recent years, Iceland has seen a surge in demand for dermatological drugs, driven by the country's high prevalence of skin conditions such as eczema and psoriasis.

Definition:
The Dermatological Drugs market covers treatments of diseases related to skin, nails, hair, and genital membranes. Typical examples are medications for eczema, acne, and rosacea. These preparations include ointments, creams, gels, pills, capsules, washing lotions, peelings, pastes, solutions, and sprays. Products which are primarily used for cosmetic purposes are not included.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Bayer, Leo Pharma, Galderma

In-Scope

  • Drugs to treat diseases related to skin, nails, hair, and genital membranes
  • Steroids such as corticosteroids (topical and systemic)
  • Topical antihistamines
  • Antifungals

Out-Of-Scope

  • Cosmetic products
  • Immunosuppressants to treat psoriasis
  • Skin cancer treatment
Dermatological Drugs: market data & analysis - Cover

Market Insights report

Dermatological Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    Iceland, a country known for its hot springs, glaciers, and Northern Lights, has a growing market for dermatological drugs.

    Customer preferences:
    Icelandic customers have shown a preference for natural and organic skincare products, which has led to an increase in demand for dermatological drugs with natural ingredients. Customers are also willing to pay a premium for products that are sustainably sourced and environmentally friendly.

    Trends in the market:
    The dermatological drugs market in Iceland is expected to grow due to an increase in skin diseases, particularly eczema and psoriasis, which are common in the country's cold and dry climate. Additionally, the aging population has led to an increase in demand for anti-aging products. The COVID-19 pandemic has also led to an increase in demand for hand sanitizers and other dermatological products.

    Local special circumstances:
    Iceland's harsh climate and long winters have led to an increase in skin diseases, making dermatological drugs a necessity for many Icelanders. The country's small population size and remote location have also led to a limited availability of certain drugs, which can drive up prices.

    Underlying macroeconomic factors:
    Iceland's strong economy and high standard of living have led to an increase in disposable income, which has allowed consumers to spend more on skincare products. The country's healthcare system also provides universal coverage for prescription drugs, which has made dermatological drugs more accessible to the population. However, the country's small market size and limited availability of certain drugs can make it challenging for companies to enter the market.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Dermatological Drugs: market data & analysis - BackgroundDermatological Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.